KRT23 and osteoporosis: Thus, together with our findings of the involvement of CK2.3 in the activation of ERK MAPK to promote osteoblastogenesis and to inhibit osteoclastogenesis, it is shown that targeting the ERK MAPK signaling pathway could potentially lead to a novel therapeutic strategy to treat osteoporosis